Clinical Trials · NCT04862143
Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 2
- Start date
- Mar 2022
- Locations
- 1 site, Sweden
- Primary endpoint
- Participant Satisfaction Assessed Through the Trial Feedback Questionnaire (TFQ)